FY2023 EPS Estimates for Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Lowered by Leerink Partnrs
Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) – Equities research analysts at Leerink Partnrs lowered their FY2023 earnings per share estimates for Xenon Pharmaceuticals in a report released on Monday, January 29th. Leerink Partnrs analyst M. Goodman now anticipates that the biopharmaceutical company will post earnings per share of ($2.87) for the year, down from […]
More Stories
US, Argentina Suggest Alternative to WHO After Both Countries Withdraw
By Jack Phillips Health officials in the U.S. and Argentine governments announced on Tuesday that they want other countries to...
CDC Stops Recommending COVID Vaccine for Healthy Children, Pregnant Women
By Zachary Stieber Health officials on May 27 announced they’re narrowing recommendations for COVID-19 vaccinations. “I couldn’t be more pleased...
Lesser-Known Provisions of the House-Passed ‘Big Beautiful Bill’
By Joseph Lord Following its passage by the House in the early morning hours of May 22, the One Big...
Royal Bank of Canada Has $15.51 Million Stake in Paramount Global (NASDAQ:PARA)
Royal Bank of Canada lowered its stake in Paramount Global (NASDAQ:PARA – Free Report) by 6.3% in the fourth quarter,...
LendingClub Co. (NYSE:LC) Shares Acquired by ProShare Advisors LLC
ProShare Advisors LLC increased its position in LendingClub Co. (NYSE:LC – Free Report) by 50.8% in the fourth quarter, according...
BNP Paribas Financial Markets Trims Stock Position in 1-800-FLOWERS.COM, Inc. (NASDAQ:FLWS)
BNP Paribas Financial Markets trimmed its holdings in 1-800-FLOWERS.COM, Inc. (NASDAQ:FLWS – Free Report) by 22.4% during the 4th quarter,...